您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > O-Acetyl Salicylhydroxamic Acid
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
O-Acetyl Salicylhydroxamic Acid
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
O-Acetyl Salicylhydroxamic Acid图片
CAS NO:199854-00-7
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议

产品介绍
Cas No.199854-00-7
别名AcSHA,O-ASHA
化学名N-(acetyloxy)-2-hydroxy benzamide
Canonical SMILESCC(=O)ONC(=O)c1ccccc1O
分子式C9H9NO4
分子量195.2
溶解度≤25mg/ml in ethanol;50mg/ml in DMSO;30mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

O-Acetyl Salicylhydroxamic Acid (O-ASHA) is an irreversible, non-selective inhibitor of COX-1 and COX-2 [1].

Cyclooxygenase (COX) is the key enzyme required for the conversion of arachidonic acid to prostaglandins. Cyclooxygenase enzymes have been involved in diverse physiological situations and disease processes ranging from inflammation to cancer. Until now, two cyclooxygenase isoforms have been identified, COX-1 and COX-2. The COX-1 enzyme is produced constitutively (i.e., gastric mucosa) and COX-2 is inducible (i.e., sites of inflammation) [2].

O-Acetyl Salicylhydroxamic Acid (O-ASHA) inhibited the activity of ovine COX-1 in a time-dependent and irreversible manner with a 50% B/B0 value of approximately 4.5 mM [1]. O-Acetyl Salicylhydroxamic Acid was a novel acetylating agent. O-Acetyl Salicylhydroxamic Acid inhibited PGE2 synthesis in vivo and blocked the cyclooxygenase activity of PGHS in vitro. O-Acetyl Salicylhydroxamic Acid elicited its effects via acetylation of Ser-529 in the cyclooxygenase active site [1].

References:
[1] Loll P J, Sharkey C T, O'Connor S J, et al.  O-acetylsalicylhydroxamic acid, a novel acetylating inhibitor of prostaglandin H2 synthase: structural and functional characterization of enzyme-inhibitor interactions[J]. Molecular pharmacology, 2001, 60(6): 1407-1413.
[2] Dubois R N, Abramson S B, Crofford L, et al.  Cyclooxygenase in biology and disease[J]. The FASEB journal, 1998, 12(12): 1063-1073.